NOAH Compendium

Printed from NOAH Compendium (https://www.noahcompendium.co.uk). (c) Copyright NOAH Compendium 2024. All Rights Reserved.
Date: Tuesday, April 23, 2024 7:03

Release 2.163
Rheumocam 15mg/ml Oral Suspension for Horses
 
Species: Horses and other equidae
Therapeutic indication: Pharmaceuticals: Anti-inflammatory preparations: Oral: Horse NSAIDs
Active ingredient: Meloxicam
Product:Rheumocam 15mg/ml Oral Suspension for Horses
Product index: Rheumocam 15mg/ml Oral Suspension for Horses
Withdrawal notes: Horse Meat and Offal: 3 days. Not authorised for use in lactating animals producing milk for human consumption.
Incorporating:
Presentation
Oral suspension. Each ml contains 15mg of meloxicam and 5mg sodium benzoate.
Uses
Meloxicam is a non-steroidal anti-inflammatory drug (NSAID) for the of alleviation of inflammation and pain in both acute and chronic musculo-skeletal disorders in horses.
Dosage and administration
To be administered either mixed with food or directly into the mouth at a dosage of 0.6 mg/kg body weight, once daily, up to 14 days. This is equivalent to 1 ml of Rheumocam per 25 kg body weight of horse. For example, a horse weighing 400 kg will receive 16 ml of Rheumocam, a horse weighing 500 kg will receive 20 ml of Rheumocam, and a horse weighing 600 kg will receive 24 ml of Rheumocam.
In case the product is mixed with food, it should be added to a small quantity of food, prior to feeding.
The suspension should be given using the Rheumocam measuring syringe provided in the package. The syringe fits onto the bottle and has a bodyweight / ml scale.
Shake well before use. Avoid introduction of contamination during use.
Contra-indications, warnings, etc
Do not use in pregnant or lactating mares.
Do not use in horses suffering from gastrointestinal disorders such as irritation and haemorrhage, impaired hepatic, cardiac or renal function and haemorrhagic disorders.
Do not use in case of hypersensitivity to the active substance or to any of the excipients.
Do not use in horses less than 6 weeks of age.
Withdrawal periods
Meat and offal: 3 days.
Not authorised for use in lactating animals producing milk for human consumption.
Adverse reactions
Isolated cases of adverse reactions typically associated with non-steroidal anti-inflammatory drugs (NSAIDs) were observed in clinical trials (slight urticaria, diarrhoea). Symptoms were reversible. In very rare cases loss of appetite, lethargy, abdominal pain and colitis have been reported. In very rare cases anaphylactoid reactions, which may be serious (including fatal), may occur and should be treated symptomatically.
If adverse reactions occur, treatment should be discontinued and the advice of a veterinarian should be sought. If you notice any serious effects or other effects not mentioned in this leaflet, please inform your veterinary surgeon.
The frequency of adverse reactions is defined using the following convention:
- very common (more than 1 in 10 animals treated displaying adverse reaction(s))
- common (more than 1 but less than 10 animals in 100 animals treated)
- uncommon (more than 1 but less than 10 animals in 1,000 animals treated)
- rare (more than 1 but less than 10 animals in 10,000 animals treated)
- very rare (less than 1 animal in 10,000 animals treated, including isolated reports).
Precautions for use in animals
If side effects occur, treatment should be discontinued and the advice of a veterinarian should be sought.
Avoid use in any dehydrated, hypovolaemic or hypotensive animal, as there is a potential risk of increased renal toxicity.
User warnings
People with known hypersensitivity to NSAIDs should avoid contact with the veterinary medicinal product.
In case of accidental ingestion, seek medical advice immediately and show this package leaflet or the label to the physician.
Use during pregnancy, lactation or lay
Laboratory studies in cattle have not provided any evidence for teratogenic, foetotoxic, or maternotoxic effects. However, no data have been generated in horses. Therefore the use in this species is not recommended during pregnancy and lactation.
Interactions
Do not administer concurrently with glucocorticoids, other non-steroidal anti-inflammatory drugs or with anti-coagulant agents.
Overdose
In the case of overdose symptomatic treatment should be initiated.
Pharmaceutical precautions
Keep out of the reach and sight of children.
This veterinary medicinal product does not require any special storage conditions.
After administration of the veterinary medicinal product, close the bottle by replacing the cap, wash the measuring syringe with warm water and let it dry.
Do not use after the expiry date (EXP) stated on the carton and the bottle.
Shelf life after first opening of the container: 3 months.
Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.
Legal category
Legal category: POM-V
Packaging quantities
HDPE bottle containing 100 or 250 ml with a tamper proof child resistant closure and a polypropylene measuring syringe.
Marketing Authorisation Number
UK (NI): 100ml - EU/2/07/078/009, 250ml - EU/2/07/078/010
UK (GB): Vm 08749/5020
Significant changes